Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

141 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Yigit R, Massuger LF, Figdor CG, Torensma R. Yigit R, et al. Among authors: torensma r. Gynecol Oncol. 2010 May;117(2):366-72. doi: 10.1016/j.ygyno.2010.01.019. Epub 2010 Feb 9. Gynecol Oncol. 2010. PMID: 20144842 Review.
Cord blood mesenchymal stem cells suppress DC-T Cell proliferation via prostaglandin B2.
van den Berk LC, Jansen BJ, Snowden S, Siebers-Vermeulen KG, Gilissen C, Kögler G, Figdor CG, Wheelock CE, Torensma R. van den Berk LC, et al. Among authors: torensma r. Stem Cells Dev. 2014 Jul 15;23(14):1582-93. doi: 10.1089/scd.2013.0433. Epub 2014 Apr 23. Stem Cells Dev. 2014. PMID: 24649980 Free PMC article.
Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System.
Wefers C, Duiveman-de Boer T, Zusterzeel PLM, Massuger LFAG, Fuchs D, Torensma R, Wheelock CE, de Vries IJM. Wefers C, et al. Among authors: torensma r. Int J Mol Sci. 2018 Jan 17;19(1):273. doi: 10.3390/ijms19010273. Int J Mol Sci. 2018. PMID: 29342108 Free PMC article.
Aiming to immune elimination of ovarian cancer stem cells.
Di J, Duiveman-de Boer T, Figdor CG, Torensma R. Di J, et al. Among authors: torensma r. World J Stem Cells. 2013 Oct 26;5(4):149-62. doi: 10.4252/wjsc.v5.i4.149. World J Stem Cells. 2013. PMID: 24179603 Free PMC article. Review.
The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.
Di J, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Massuger LF, Torensma R. Di J, et al. Among authors: torensma r. Cell Oncol (Dordr). 2013 Oct;36(5):363-74. doi: 10.1007/s13402-013-0142-8. Epub 2013 Aug 9. Cell Oncol (Dordr). 2013. PMID: 23928726
Functional OCT4-specific CD4+ and CD8+ T cells in healthy controls and ovarian cancer patients.
Di J, Massuger LF, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Torensma R. Di J, et al. Among authors: torensma r. Oncoimmunology. 2013 May 1;2(5):e24271. doi: 10.4161/onci.24271. Epub 2013 Apr 1. Oncoimmunology. 2013. PMID: 23762805 Free PMC article.
Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
Wefers C, Lambert LJ, Torensma R, Hato SV. Wefers C, et al. Among authors: torensma r. Gynecol Oncol. 2015 May;137(2):335-42. doi: 10.1016/j.ygyno.2015.02.019. Epub 2015 Feb 26. Gynecol Oncol. 2015. PMID: 25727651 Review.
Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.
Vasaturo A, Verdoes M, de Vries J, Torensma R, Figdor CG. Vasaturo A, et al. Among authors: torensma r. Immunobiology. 2015 Feb;220(2):243-8. doi: 10.1016/j.imbio.2014.11.007. Epub 2014 Nov 15. Immunobiology. 2015. PMID: 25466585 Review.
Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.
Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG. Cruz LJ, et al. Among authors: torensma r. Nanomedicine (Lond). 2012 Oct;7(10):1591-610. doi: 10.2217/nnm.12.131. Nanomedicine (Lond). 2012. PMID: 23148541 Review.
Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue.
Prinsen H, van Laarhoven HW, Pots JM, Duiveman-de Boer T, Mulder SF, van Herpen CM, Jacobs JF, Leer JW, Bleijenberg G, Stelma FF, Torensma R, de Vries IJ. Prinsen H, et al. Among authors: torensma r. Hum Vaccin Immunother. 2015;11(7):1634-40. doi: 10.1080/21645515.2015.1040207. Hum Vaccin Immunother. 2015. PMID: 25996472 Free PMC article.
141 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback